ArticleMolecular and clinical oncology2026
Correlation of high PRDX4 expression with poor prognosis in patients with ESCA: Bioinformatics and
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer (ESCA) is a highly lethal gastrointestinal malignancy with limited therapeutic options. The peroxiredoxin 4 (PRDX4) protein has antioxidant functions and is implicated in various types of cancer, but its role in ESCA remains poorly understood. The purpose of the present study was to investigate PRDX4 expression in ESCA, evaluate its clinical prognostic value, and explore associations with the tumor immune microenvironment and metabolic pathways, with validation by immunohistochemistry (IHC). PRDX4 expression in ESCA was analyzed using UALCAN, SANGERBOX, TIMER, STRING and Kaplan-Meier Plotter databases. IHC was performed on 60 ESCA and matched normal tissues. Associations with overall survival (OS), progression-free interval (PFI), disease-specific survival (DSS), disease-free interval (DFI), TNM stage and immune cell infiltration were examined. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were conducted. PRDX4 was significantly upregulated in ESCA tissues (P<0.05). IHC showed strong positive staining in all 60 tumor tissues vs. 11/60 normal tissues (P<0.05). High PRDX4 expression correlated with poorer OS [Hazard ratio (HR)=1.82; 95% confidence interval (CI): 1.21-2.74; P=0.004], PFI (HR=1.65; 95% CI: 1.08-2.52; P=0.019) and DSS (HR=2.01; 95% CI: 1.32-3.06; P<0.001), but not with DFI (P=0.35). PRDX4 levels differed significantly across N stages (P=0.006), but not T or M stages. Furthermore, PRDX4 expression was significantly associated with tumor differentiation (P=0.028) and showed a trend towards larger tumor size (P=0.061). PRDX4 expression correlated with infiltration of dendritic cells, macrophages, CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.